Associate Professor Michael Holmes
BSc(Hons) MBBS MSc(Epidemiology) PhD MRCP
- Clinical Trial Service Unit and Epidemiological Studies Unit
Michael Holmes studied Medicine at University of St Andrews and University College London, graduating in 2005. Working in the NHS as a hospital physician, he held NIHR clinical academic posts including academic foundation year and an academic clinical fellowship in Clinical Pharmacology and Therapeutics/General Internal Medicine. Michael then undertook a Masters in Epidemiology at London School of Hygiene and Tropical Medicine and completed a PhD in Genetic Epidemiology at University College London. Following his PhD, he was Assistant Professor at University of Pennsylvania, Philadelphia, USA, where he investigated genetic determinants of clinical outcomes following organ transplantation.
Michael is a Senior Clinical Research Fellow in Cardiovascular Medicine at CTSU. He is working within the China Kadoorie Biobank (CKB) to investigate causal risk factors underpinning cardiovascular disease and cancer subtypes. Michael's expertise lies in using genetic variants to disentangle causality from confounding with the aim of improving understanding of disease aetiology and identifying novel therapeutic targets for disease prevention.
Integrating genomics with biomarkers and therapeutic targets to invigorate cardiovascular drug development.
Holmes MV. et al, (2021), Nat Rev Cardiol
NMR metabolite profiles in male meat-eaters, fish-eaters, vegetarians and vegans, and comparison with MS metabolite profiles
SCHMIDT J. et al, (2021), Metabolites
Using Mendelian Randomization to Improve the Design of Randomized Trials.
Ference BA. et al, (2021), Cold Spring Harb Perspect Med
Genetic IL-6R variants and therapeutic inhibition of IL-6 receptor signalling in COVID-19 – Authors' reply
Bovijn J. et al, (2021), The Lancet Rheumatology
Metabolic profiling of angiopoietin-like protein 3 and 4 inhibition: a drug-target Mendelian randomization analysis.
Wang Q. et al, (2020), Eur Heart J